Pembrolizumab + Lenvatinib
Treatment for Kidney Cancer
Typical Dosage: Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks, Lenvatinib 20 mg oral once daily
Effectiveness
90%
Safety Score
30%
Clinical Trials
26
Participants
355
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks, Lenvatinib 20 mg oral once daily
Time to Effect
2-3 months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$285,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$616,000/QALY
QALYs Gained
1.63
Outcome-Based Costs
Cost per Responder
$401,408
Cost per Remission
$1,781,250
Comparison vs Sunitinib
Cost Difference
+$165,000/year
More expensive
QALY Difference
+1.63 QALYs
Better outcomes
Dominance
No dominance
Pembrolizumab + Lenvatinib Outcomes
for Kidney Cancer
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+71%
Remission Rate
+16%
Common Side Effects
Hypertension
+50%
Diarrhea
+56%
Fatigue
+49%
Hypothyroidism
+40%
Stomatitis
+35%
Proteinuria
+30%
Sources:
Active Clinical Trials
12 active trials recruiting for Pembrolizumab + Lenvatinib in Kidney Cancer
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
NCT05899049ACTIVE NOT RECRUITINGPHASE3
249 participants
INTERVENTIONAL
Beijing, China +16 more
Started: Jul 27, 2022
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706ACTIVE NOT RECRUITINGPHASE3
1.65K participants
INTERVENTIONAL
Birmingham, United States +261 more
Started: Apr 14, 2021
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506ACTIVE NOT RECRUITINGPHASE1
45 participants
INTERVENTIONAL
Beijing, China +4 more
Started: Oct 13, 2021
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
NCT06962787RECRUITINGPHASE2
260 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 28, 2025
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479ACTIVE NOT RECRUITINGPHASE1, PHASE2
400 participants
INTERVENTIONAL
San Francisco, United States +54 more
Started: Dec 16, 2020
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518ACTIVE NOT RECRUITINGPHASE1, PHASE2
370 participants
INTERVENTIONAL
San Francisco, United States +50 more
Started: Dec 17, 2020
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
NCT05733715RECRUITINGEARLY_PHASE1
30 participants
INTERVENTIONAL
Philadelphia, United States
Started: May 3, 2023
CARE1 Pragmatic Clinical Trial
NCT06364631RECRUITINGPHASE3
1.25K participants
INTERVENTIONAL
Vienna, Austria +45 more
Started: Apr 12, 2024
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861ACTIVE NOT RECRUITINGPHASE3
1.07K participants
INTERVENTIONAL
Stanford, United States +182 more
Started: Oct 13, 2016
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
NCT04393350ACTIVE NOT RECRUITINGPHASE2
18 participants
INTERVENTIONAL
Atlanta, United States
Started: Jun 22, 2020
Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
NCT05319015RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Dallas, United States
Started: Jan 6, 2023
International Multicentric Study ARON-1
NCT05287464RECRUITING
1.22K participants
OBSERVATIONAL
Macerata, Italy
Started: Mar 10, 2022
Completed Clinical Trials
5 completed trials for Pembrolizumab + Lenvatinib in Kidney Cancer
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
NCT04704219COMPLETEDPHASE2
160 participants
INTERVENTIONAL
Washington D.C., United States +55 more
Started: Feb 23, 2021
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
NCT05485896COMPLETEDPHASE2
23 participants
INTERVENTIONAL
Tianjin, China
Started: Jul 1, 2022
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
NCT03006887COMPLETEDPHASE1
6 participants
INTERVENTIONAL
Chuo-ku, Japan
Started: Jan 12, 2017
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
NCT06345183COMPLETED
327 participants
OBSERVATIONAL
Dublin, United States
Started: Feb 19, 2024
A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients
NCT05375136COMPLETED
135 participants
OBSERVATIONAL
Bundang, South Korea +18 more
Started: Jun 25, 2021
Showing 20 of 27 total trials